GlassScriptPhysician profile
George Tripp
NPI 1306062526
$2,628.81
in general payments reported to CMS, 2019-2025
39 companies · $300 in 2025
The $300 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $289 · 2021: $462 · 2022: $277 · 2023: $478 · 2024: $490 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $302.63 | 2019-2024 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $220.10 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.80 | 2019-2024 | Xifaxan, Trulance |
| Harmony Biosciences LLC | $166.97 | 2023-2025 | Wakix |
| Glaxosmithkline, LLC. | $154.56 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $146.51 | 2020-2025 | Wegovy |
| Lilly USA, LLC | $127.11 | 2019-2024 | Jardiance, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $90.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.61 | 2019-2022 | |
| Pfizer INC. | $87.84 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.44 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $76.30 | 2019-2025 | Rotateq, Vaxneuvance, Capvaxive |
| Abbott Laboratories | $66.86 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $63.13 | 2019-2023 | Jornay Pm |
| Abbvie INC. | $55.29 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $54.64 | 2019-2024 | Flumist Quadrivalent, Farxiga |
| Organon LLC | $53.34 | 2022-2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $51.33 | 2024-2025 | |
| Sobi, INC | $48.73 | 2021-2023 | |
| Sanofi Pasteur INC. | $47.06 | 2021 | |
| Antares Pharma, INC. | $43.27 | 2023 | Tlando, Xyosted, Nocdurna |
| Dynavax Technologies Corporation | $36.31 | 2021-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $32.63 | 2024-2025 | Inspire |
| Cranial Technologies, INC | $32.27 | 2019-2020 | |
| Halozyme INC | $31.02 | 2023 | |
| Amgen INC. | $29.92 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.43 | 2025 | |
| Amarin Pharma, INC. | $28.08 | 2021 | |
| Corium, LLC | $25.79 | 2023 | Azstarys |
| Genentech USA, INC. | $23.68 | 2019-2021 | |
| Shire North American Group INC | $22.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.43 | 2021 | |
| Orthofix Medical, INC. | $18.34 | 2023 | Physio-Stim |
| Becton, Dickinson and Company | $16.02 | 2025 | Bd Onclarity |
| Shield Therapeutics INC | $15.78 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.49 | 2021 | |
| Daiichi Sankyo INC. | $13.35 | 2023 | Injectafer |
| Medtronic, INC. | $12.45 | 2021 | |
| Lucid Diagnostics INC. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Tripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.